Trial · NCT03543657
Maintenance Treatment of Renal Anemia in Dialysis Subjects
NCT03543657, Phase 3, Completed, Bayer
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Maintenance Treatment of Renal Anemia in Dialysis Subjects. Trials, record NCT03543657. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03543657
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Maintenance Treatment of Renal Anemia in Dialysis Subjects
- NCT number
- NCT03543657
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 229 participants, actual
- Lead sponsor
- Bayer
- Conditions
- Anemia, Renal Insufficiency, Chronic
- Interventions
- Molidustat (BAY85-3934), Darbepoetin alfa, Placebo of Molidustat (BAY85-3934), Placebo of Darbepoetin alfa
- First posted
- 2018-06-01
- Last updated
- 2021-01-29
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The mean Hb level during the evaluation period | From week 33 to 36 | |
| Primary | The change in mean Hb level during the evaluation period from baseline | Baseline and week 33 to 36 | |
| Secondary | Responder rate: proportion of responders among the subjects | From week 33 to 36 | Responder is defined as meeting all of the following criteria: (i) Mean of the Hb levels in the target range (ii) ≥ 50% of the Hb levels in the target range (iii) No rescue treatment |
| Secondary | Proportion of subjects who meet each component of the response | From week 33 to 36 | Response: (i) Mean of the Hb levels in the target range (ii) ≥ 50% of the Hb levels in the target range (iii) No rescue treatment |
| Secondary | Hb level | Up to 52 weeks | |
| Secondary | Change in Hb level | Baseline and up to 52 weeks | |
| Secondary | Proportion of subjects whose mean hemoglobin level is in the target range | From week 33 to 36 | |
| Secondary | Proportion of subjects whose mean hemoglobin level is above the target range | From week 33 to 36 | |
| Secondary | Proportion of subjects whose mean hemoglobin level is below the target range | From week 33 to 36 | |
| Secondary | Proportion of subjects with hemoglobin levels in the target range | Up to 52 weeks |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03543657
GET https://conductscience.org/api/trials/v1/NCT03543657/registered